Filtered By:
Drug: Actos

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 156 results found since Jan 2013.

The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone
Source: Journal of Diabetes - June 7, 2016 Category: Endocrinology Authors: Silvio E. Inzucchi, Karen L. Furie Tags: Commentary Source Type: research

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Abstract During the last decade, the armamentarium for glucose-lowering drugs has increased enormously by the development of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors, allowing individualization of antidiabetic therapy for patients with type 2 diabetes (T2DM). Some combinations can now be used without an increased risk for severe hypoglycemia and weight gain. Following a request of the US Food and Drug Administration, many large cardiovascular (CV) outcome studies have been performed in patients with longstanding disease and established CV disease. In the majority of CV outcome studies, CV ris...
Source: Clinical Therapeutics - May 18, 2016 Category: Drugs & Pharmacology Authors: Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH Tags: Clin Ther Source Type: research

Diabetes drug pioglitazone could get personal: Neither panacea, nor peril
When I was in training, one of my beloved mentors declared, “I never use a drug until it’s been on the market for 20 years.” I was young enough then that I couldn’t fathom being a doctor for 20 years, let alone waiting two decades to use a new drug. As my career has progressed, I’ve seen many new drugs released to the market. Some of them are truly miraculous, bringing people longer, healthier, and more productive lives. Many of them have not withstood the test of time. More than a few have even been taken off the market. Even though the Food and Drug Administration diligently reviews each new medicine before it...
Source: New Harvard Health Information - May 5, 2016 Category: Consumer Health News Authors: Lori Wiviott Tishler, MD, MPH Tags: Diabetes Drugs and Supplements pioglitazone thiazolidinediones Source Type: news

Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor
The recently completed EMPA‐REG study showed that empagliflozin significantly decreased the major adverse cardiac events (MACE) endpoint, which comprised cardiovascular death, non‐fatal myocardial infarction (MI) and stroke, in patients with high‐risk type 2 diabetes (T2DM), primarily through a reduction in cardiovascular death, without a significant decrease in either MI or stroke. In the PROactive study, pioglitazone decreased the MACE endpoint by a similar degree to that observed in the EMPA‐REG study, through a marked reduction in both recurrent MI and stroke and a modest reduction in cardiovascular death. Thes...
Source: Diabetes, Obesity and Metabolism - April 5, 2016 Category: Endocrinology Authors: R. A. DeFronzo, R. Chilton, L. Norton, G. Clarke, R. E. J. Ryder, M. Abdul‐Ghani Tags: PERSPECTIVE Source Type: research

News from the International Stroke Conference: Pioglitazone Found to Be Associated with a Lower Risk of Secondary Stroke in Non-Diabetic Patients with Insulin Resistance
No abstract available
Source: Neurology Today - March 17, 2016 Category: Neurology Tags: Features Source Type: research

Cerebrovascular disease: Pioglitazone reduces risk of stroke or MI
Nature Reviews Cardiology 13, 182 (2016). doi:10.1038/nrcardio.2016.34 Author: Karina Huynh Insulin resistance is present in >50% of patients without diabetes who have had an ischaemic stroke or a transient ischaemic attack (TIA). The IRIS trial investigators hypothesized that pioglitazone, an insulin-sensitizing agent, could reduce rates of stroke and myocardial infarction (MI) after ischaemic stroke or
Source: Nature Reviews Cardiology - March 3, 2016 Category: Cardiology Authors: Karina Huynh Tags: Research Highlight Source Type: research

Diabetes Drug May Stop Stroke, Help Lipids
Pioglitazone may prevent repeated cardiovascular events in some patients. Combined with omega-3 fatty acids, the drug also can improve lipid metabolism.
Source: ConsultantLive - March 1, 2016 Category: Internal Medicine Authors: Mark L. Fuerst Tags: Cardiovascular Diseases News Diabetes Source Type: news

Targeting insulin resistance after stroke cuts cardiovascular risk
Large trial shows pioglitazone could reduce risk of cardiovascular events or diabetes in stroke patients
Source: Clinical Pharmacist - February 26, 2016 Category: Drugs & Pharmacology Source Type: research

New front opens in battle against stroke
Medical scientists have vetted a potentially powerful new tool for helping prevent stroke and heart attack. In a study, researchers show that pioglitazone, a member of the insulin-sensitizing class of medications called thiazolidinediones, reduced the risk of stroke or heart attack by almost a quarter in patients who had previously suffered a stroke or mini-stroke.
Source: ScienceDaily Headlines - February 25, 2016 Category: Science Source Type: news

Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
ABSTRACT The recently completed EMPA‐REG study demonstrated that empagliflozin significantly decreased the MACE endpoint (cardiovascular death, nonfatal MI, stroke) in high risk type 2 diabetic patients, primarily due to a reduction in cardiovascular death, without a significant decrease in either myocardial infarction or stroke. In PROactive, pioglitazone decreased the MACE endpoint by a similar degree to that in EMPA‐REG, due to a marked reduction in both recurrent myocardial infarction and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to c...
Source: Diabetes, Obesity and Metabolism - February 25, 2016 Category: Endocrinology Authors: Ralph A. DeFronzo, Robert Chilton, Luke Norton, Geoffrey Clarke, Robert E.J. Ryder, Muhammad Abdul‐Ghani Tags: ORIGINAL ARTICLE Source Type: research

PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week's topics include testosterone in older men, carotid procedures in those without symptoms, pioglitazone after a stroke, and managing Ebola in the U.S. and Europe
Source: MedPage Today Cardiovascular - February 20, 2016 Category: Cardiology Source Type: news

VIDEO: Post-stroke pioglitazone modestly protective against secondary vascular events
LOS ANGELES – Nondiabetic, insulin-resistant patients who started pioglitazone within 6 months of an ischemic stroke or transient ischemic attack had almost a 3% absolute risk reduction in secondary...
Source: Clinical Endocrinology News - February 19, 2016 Category: Endocrinology Source Type: news